Latest Patent Protection News

EcoGraf Limited has been granted a second Australian patent for its HFfree® purification technology, reinforcing its position in the sustainable battery materials market. This patent extends protection for its innovative graphite purification process critical to lithium-ion battery anode production and recycling.

Next Science Limited has successfully had a derivative complaint dismissed in Florida, while continuing legal action against former employees for breach of post-employment restraints.

Dimerix Limited has announced a US licensing transaction for its Phase 3 asset DMX-200 targeting FSGS, alongside progress updates on its clinical trial. The move underscores the company’s push to address a rare kidney disease with no approved therapies.

Recce Pharmaceuticals reports strong Phase II clinical trial results for its topical anti-infective R327G, achieving a 93% efficacy rate in treating ABSSSI, alongside a significant capital raise to fund upcoming Phase III trials.

BluGlass Limited has achieved a world-record 1250mW single-mode GaN laser chip and strengthened its commercial pipeline with a $120,000 repeat order, positioning itself for rapid growth in photonics markets.

Sparc Technologies has progressed to Stage 2 of its Sparc Hydrogen joint venture with pilot plant commissioning slated for mid-2025, while also securing its first patent for photocatalytic water splitting technology in Morocco. Concurrently, its graphene-based additive ecosparc® demonstrates promising field trial results, underpinning commercial momentum.

Imugene Limited reports encouraging Phase 1b results for azer-cel in lymphoma, secures FDA Fast Track status, and strengthens patent portfolio while raising A$20 million to fuel ongoing immuno-oncology programs.

Zelira Therapeutics has enhanced its financial flexibility through a $1.15 million R&D tax refund and a $1 million At-the-Market equity facility, while progressing FDA trial preparations for its HOPE® 1 autism treatment.

Neurizon Therapeutics has been granted a pivotal US patent for its lead drug candidate NUZ-001, extending protection until 2039 and enhancing its commercial and clinical positioning in neurodegenerative disease treatment.

BluGlass Limited has secured over A$4 million in new contracts and filed three US patents for high-power tunable GaN lasers, reinforcing its leadership in visible laser technology and expanding its footprint in strategic photonics markets.

First Graphene Limited reports a robust December quarter with new patents, expanded distribution networks, and advancing commercial trials, positioning the company on a path to cash breakeven.

Codeifai Limited has terminated its exclusive licence with MIT and launched a strategic review of its material science division, signaling a decisive pivot towards digital and AI-driven brand solutions.